A Single-Patient Study Using AGS 006
Completed · Not applicable
Conditions studied: Pancreatic Cancer
In brief
Argos Therapeutics, Inc., (Argos) proposes to study AGS-006 in a subject with newly diagnosed resectable pancreatic cancer. The AGS 006 immunotherapeutic may potentially offer a desired additional option to conventional treatments for pancreatic carcinoma.
Key facts
- Study ID
- NCT00664482
- Run by
- Argos Therapeutics
- People needed
- 1
- Starts
- 2007-05-01
- Expected to finish
- 2011-10-01
- Last updated by the study team
- 2013-01-29
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
You may qualify if…
- A male subject 18 years of age or older with newly diagnosed resectable pancreatic cancer who, in the opinion of the investigator, is suitable for participation in the study will be eligible for inclusion if all of the following criteria apply:
- Able to abstain from taking prohibited prescription or prohibited non-prescription drugs.
- Ability to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements.
- Voluntary informed consent given to participate in the study.
You may not qualify if…
- Any serious medical condition such as cardiopulmonary disease, circulatory compromise, hepatic or renal dysfunction, or other illness considered by the investigator to constitute an unwarranted high risk for investigational treatment.
- Active autoimmune disease including, but not limited to:
- Active, acute, or chronic clinically significant infections including human immunodeficiency virus (HIV) and viral hepatitis.
- Known hypersensitivity to dimethyl sulfoxide (DMSO).
- Body weight less than 30 kg.
Where it is running
- Rockefeller University — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.